• Privacy policy
  • T&C’s
  • About Us
    • FAQ
  • Contact us
  • Guest Content
  • TLE
  • News
  • Politics
  • Opinion
    • Elevenses
  • Business
  • Food
  • Travel
  • Property
  • JOBS
  • All
    • All Entertainment
    • Film
    • Sport
    • Tech/Auto
    • Lifestyle
    • Lottery Results
      • Lotto
      • Set For Life
      • Thunderball
      • EuroMillions
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
The London Economic
No Result
View All Result
Home Prices and Markets

Sareum Holdings – Tyking over… nicely

Sareum Holdings – Tyking over… nicely Sareum’s investment case centres on the development and potential out-licensing of its two internal, preclinical-stage TYK2/JAK1 inhibitors, which are proceeding towards IND (investigational new drug) filings in 2020. Development of Sareum’s Chk1 inhibitor, SRA737, is ongoing for now, but is likely to see a pause, while Sareum’s partner, Sierra Oncology, […]

Edward Marten by Edward Marten
2019-12-10 15:34
in Prices and Markets
FacebookTwitterLinkedinEmailWhatsapp

Sareum Holdings – Tyking over… nicely

Sareum’s investment case centres on the development and potential out-licensing of its two internal, preclinical-stage TYK2/JAK1 inhibitors, which are proceeding towards IND (investigational new drug) filings in 2020. Development of Sareum’s Chk1 inhibitor, SRA737, is ongoing for now, but is likely to see a pause, while Sareum’s partner, Sierra Oncology, attempts to secure a sub-licensing deal following a change in its own strategic priorities. The uncertainty created by this decision has weighed on Sareum’s share price, despite trials of SRA737 yielding some promising early data and highlighting a fast-to-market development plan.

However, increased visibility of Sareum’s cancer-focused TYK2 programme SDC-1802 and progress with the previously higher profile autoimmune candidate SDC-1801 has led to an increase in the notional value of the two combined TYK2i assets to c.£20-25m in QuotedData’s model. However, uncertainty over SRA737’s future has led to a hopefully reduction in the value of this asset, previously estimated at £20m in QuotedData’s model.

Within QuotedData’s model, these two countervailing effects suggest that a current value for Sareum now lies in the £20-25m range (0.65-0.81p/share), versus the previously published £25-35m (after normal assumptions for research and development, corporate overheads and tax). Despite the overall fall, the new valuation still offers up to 92% upside against the current share price. There is also the potential for further gains if a satisfactory resolution to the uncertainty over SRA737’s future can be found (see page 8).

RelatedPosts

Is Spread Betting Gambling or Investing? Ethics, Risks and Rewards

The Wealth Formula: How Much is One Minute of a Market Emperor Worth?

How the UK’s Financial Market is Adapting to New Digital Trends

Understanding the full spectrum of services offered by cryptocurrency exchanges

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: [email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

No Result
View All Result
  • Home
  • News
  • Politics
  • Lottery Results
    • Lotto
    • Set For Life
    • Thunderball
    • EuroMillions
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Privacy policy
  • Contact us

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

← 88% of Conservatives’ most widely promoted ads feature claims which are not correct ← The Tories want you to vote for an alternate reality. Don’t fall for it
No Result
View All Result
  • Home
  • News
  • Politics
  • Lottery Results
    • Lotto
    • Set For Life
    • Thunderball
    • EuroMillions
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Privacy policy
  • Contact us

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

-->